New medications for heart failure

详细信息    查看全文

• 作者：Jonathan S. Gordin ; MD^a ; Gregg C. Fonarow ; MD^a ; ^b ; ^{gfonarow@mednet.ucla.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Heart failure therapies ; Funny channel ; Neprilysin ; Sacubitril/valsartan ; Ivabradine
• 刊名：Trends in Cardiovascular Medicine
• 出版年：2016
• 出版时间：August 2016
• 年：2016
• 卷：26
• 期：6
• 页码：485-492
• 全文大小：630 K

文摘

Heart failure is common and results in substantial morbidity and mortality. Current guideline-based therapies for heart failure with reduced ejection fraction, including beta blockers, angiotensin converting enzyme (ACE) inhibitors, and aldosterone antagonists aim to interrupt deleterious neurohormonal pathways and have shown significant success in reducing morbidity and mortality associated with heart failure. Continued efforts to further improve outcomes in patients with heart failure with reduced ejection fraction have led to the first new-in-class medications approved for heart failure since 2005, ivabradine and sacubitril/valsartan. Ivabradine targets the I_f channels in the sinoatrial node of the heart, decreasing heart rate. Sacubitril/valsartan combines a neprilysin inhibitor that increases levels of beneficial vasodilatory peptides with an angiotensin receptor antagonist. On a background of previously approved, guideline-directed medical therapies for heart failure, these medications have shown improved clinical outcomes ranging from decreased hospitalizations in a select group of patients to a reduction in all-cause mortality across all pre-specified subgroups. In this review, we will discuss the previously established guideline-directed medical therapies for heart failure with reduced ejection fraction, the translational research that led to the development of these new therapies, and the results from the major clinical trials of ivabradine and sacubitril/valsartan.